ASCO® 2023 Insights: "10-Year Update of the Short-HER Phase III Randomized Trial - Nine-Weeks vs. One-Year Trastuzumab for Early-Stage HER2+ BC"

751 views
June 15, 2023
0 Comments
Login to view comments. Click here to Login